CardiaTec Bio
CardiaTec enables cardiovascular drug discovery by turning multi-omics data into actionable targets. It uses AI and computational modelling on a proprietary human cardiac multiomics dataset enriched with clinical annotations. The company operates as a B2B biotech platform that identifies first-in-class targets for cardiovascular therapies. Its network includes 65 hospitals and collaboration with leading pharma experts, enabling rapid translation toward clinics. The approach targets scalable precision therapies and broader cardiovascular disease programs.
CardiaTec Bio
CardiaTec enables cardiovascular drug discovery by turning multi-omics data into actionable targets. It uses AI and computational modelling on a proprietary human cardiac multiomics dataset enriched with clinical annotations. The company operates as a B2B biotech platform that identifies first-in-class targets for cardiovascular therapies. Its network includes 65 hospitals and collaboration with leading pharma experts, enabling rapid translation toward clinics. The approach targets scalable precision therapies and broader cardiovascular disease programs.